Department of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Institute of Thoracic Oncology, Fudan University, Shanghai, China.
Cancer Med. 2023 Jun;12(11):12452-12461. doi: 10.1002/cam4.5955. Epub 2023 Apr 19.
The role of postoperative radiotherapy (PORT) in malignant pleural mesothelioma (MPM) remains controversial and the eighth edition TNM staging scheme for MPM has not been fully verified. We aimed to develop an individualized prediction model for identifying optimal candidates for PORT among MPM patients who received surgery plus chemotherapy and externally validate the performance of the new TNM staging scheme.
Detailed characteristics of MPM patients during 2004-2015 were retrieved from SEER registries. Propensity score matching (PSM) was conducted to reduce disparities of baseline characteristics (age, sex, histologic type, stage, and type of surgery) between the PORT group and no-PORT group. A novel nomogram was constructed based on independent prognosticators identified by multivariate Cox regression model. The discriminatory performance and degree of calibration were evaluated. We stratified patients into different risk groups according to nomogram total scores and estimated the survival benefit of PORT in different subgroups in order to identify the optimal candidates.
We identified 596 MPM patients, among which 190 patients (31.9%) received PORT. PORT conferred significant survival benefit in the unmatched population, while there was no significant survival difference favoring PORT in the matched population. The C-index of the new TNM staging scheme was closed to 0.5, which represented a poor discriminatory ability. A novel nomogram was constructed based on clinicopathological factors, including age, sex, histology, and N stage. We stratified patients into three risk groups. Subgroup analyses indicated that PORT was beneficial for high-risk group (p = 0.003) rather than low-risk group (p = 0.965) and intermediate-risk group (p = 0.661).
We established a novel predictive model, which could make individualized prediction of survival benefit of PORT for MPM and could compensate for weakness in TNM staging system.
术后放疗(PORT)在恶性胸膜间皮瘤(MPM)中的作用仍存在争议,第八版 MPM 的 TNM 分期方案尚未得到充分验证。我们旨在为接受手术加化疗的 MPM 患者制定一个个体化的预测模型,以确定 PORT 的最佳候选者,并对外验证新 TNM 分期方案的性能。
从 SEER 登记处检索了 2004-2015 年间 MPM 患者的详细特征。采用倾向评分匹配(PSM)来减少 PORT 组和非 PORT 组之间基线特征(年龄、性别、组织学类型、分期和手术类型)的差异。基于多变量 Cox 回归模型确定的独立预后因素,构建了一个新的列线图。评估了判别性能和校准程度。根据列线图总分将患者分层为不同的风险组,并估计不同亚组中 PORT 的生存获益,以确定最佳候选者。
我们共纳入 596 例 MPM 患者,其中 190 例(31.9%)接受了 PORT。在未匹配人群中,PORT 显著改善了生存,而在匹配人群中,PORT 无显著生存获益。新 TNM 分期方案的 C 指数接近 0.5,表明其判别能力较差。基于临床病理因素,包括年龄、性别、组织学和 N 分期,构建了一个新的列线图。我们将患者分为三个风险组。亚组分析表明,PORT 对高危组(p=0.003)有益,而对低危组(p=0.965)和中危组(p=0.661)无益。
我们建立了一个新的预测模型,可以对 MPM 患者 PORT 的生存获益进行个体化预测,并可以弥补 TNM 分期系统的不足。